Neurol. praxi. 2012;13(3):127-130

Parkinsonian syndromes: MSA and PSP as characteristic examples

MUDr.Pavel Ressner, Ph.D.1,2,3, MUDr.Petra Bártová, Ph.D.1,3
1 Ambulance pro diagnostiku a léčbu extrapyramidových poruch a Kognitivní centrum,
Neurologická klinika FN Ostrava
2 Lékařská fakulta Ostravské Univerzity, Ostrava
3 Lékařská fakulta Univerzity Palackého, Olomouc

Parkinsonian syndromes are a large and heterogeneous group of diseases. The classification of these diseases has been making a rapid

progress and, due to advances in the field of molecular genetics in particular, it may be possible to distinguish new nosological entities in the

future. Atypical parkinsonian syndromes can be divided into synucleinopathies and tauopathies, and other heredodegenerative diseases.

Parkinsonian syndromes are most characteristically represented by multiple system atrophy (MSA) and progressive supranuclear palsy (PSP),

with PSP being a type of tauopathy and MSA that of synucleinopathy. The present article provides general information on MSA and PSP.

Keywords: Parkinsonian syndromes, multiple system atrophy, progressive supranuclear palsy

Published: May 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ressner P, Bártová P. Parkinsonian syndromes: MSA and PSP as characteristic examples. Neurol. praxi. 2012;13(3):127-130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bednařík J, Ambler Z, Růžička E, a kol. Klinická neurologie, část speciální I. Praha. Triton, 2010: 707.
    2. Ben-Shlomo Y, Wenning GK, Tisson F, Quinn NP. Survival pf patiens with patologicaly proven multiple systém atrophy: a meta analysis. Neurology. 1997; 48: 384-393. Abstract. Go to original source... Go to PubMed...
    3. Dalvi AI. Parkinson-Pplus syndromes. Medscape reference. 2011. Dostupné na http://emedicine.medscape.com/article/1154074-overiview.
    4. Dubois S, Slachevsky A, Pillon B, Beato R, Villaponda JM, Litvan I., ,Applause" sign helps to discriminate PSPfrom FTD and PD. Neurology. 2005; 64(12): 2132-2133. Go to original source... Go to PubMed...
    5. Farníková K, Bareš M, Nestrašil I, Kaňovský P. Parkinsonské fenotypy - na cestě k nové nozologii atypických parkinsonských syndrom. Cesk Slov Neurol N 2011; 74(6): 641-653.
    6. Geser F, Wenning GK. Multiple System Atrophy. In: Litvan I, editor. Atypical Parkinsonian Disorders: Clinical and Research Aspects. Totoxa, NJ: Human Press; 2005: 335-360. Go to original source...
    7. Gilman S, Low PA, Quit N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis on multiple system atrophy. J Auton Nerv Syst 1998; 74(2-3): 189-192. Go to original source... Go to PubMed...
    8. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Qionn NJ, Revesz T, Robertson D, Sandroni P, Seppi K, Vidalhet M. Second consesus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71: 670-676. Go to original source... Go to PubMed...
    9. Goedert M, Jakes R. Mutations causing neurodegenerative tauopaties. Biochim Biophys Acta. 2005; 1739(2-3): 240-250. Go to original source... Go to PubMed...
    10. Graham JG, Oppenheimer DR. Ortostatic hypotension ane nicotine senzitivity in case of multiple systém atrophy. J Neurol Neurosurg Psychiatry 1969; 32: 28. Go to original source... Go to PubMed...
    11. Litvan I, Agid Y, Calne D, Cambell G, Dubois B, Duvoisin RC. Climnical research kriteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47(1): 1-9. Go to original source... Go to PubMed...
    12. O´Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, Reversz T, Lees AJ. Clinical outcomes of progressive supranuclear palsy and multiple systém atrophy. Brain. 2008; 131: 1362-1372. Go to original source... Go to PubMed...
    13. Steele JC. PSP Steele-Richardson-Olszewski syndrome Richardson´s dinase. J Neurol Sci 2009; 285(Suppl 1): 25. Go to original source...
    14. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn SE. Clinical features and natural history of multiple systém atrophy. An analysis of 100 cases. Brain. 1994; 117: 835-845. Abstract. Go to original source... Go to PubMed...
    15. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple systém atrophy. Lancet Neurology 2004; 3: 93-103. Go to original source... Go to PubMed...
    16. Watanabe H, Saito Y, Terao S. Progression and prognosis in multiple system atrophy: An analysis of 230 Japanese patients. Brain 2002; 125: 1070-1083. Go to original source... Go to PubMed...
    17. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L. Characteristics of two distinct clinical phenotypes in patologically proven progressive supranuclear palsy: Richardson´s syndrome and PSP-parkinsonism. Brain.2005; 128: 1247-1258. Go to original source... Go to PubMed...
    18. Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure Akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22: 2235-2241. Go to original source... Go to PubMed...
    19. Wolters EC, Laar T, Berendse HW. Parkinsonism and realted Disorders.Amsterodam: VU University Press 2007: 251-523.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.